Gay Men’s Health Crisis Calls for HIV Reporting in New York

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 2
Volume 7
Issue 2

NEW YORK-The Gay Men’s Health Crisis (GMHC), the country’s premier nonprofit AIDS service group, has changed its thinking on HIV reporting. The agency is calling for a change in state policy that would require New York physicians to report cases of HIV infection to the state’s health department.

NEW YORK—The Gay Men’s Health Crisis (GMHC), the country’s premier nonprofit AIDS service group, has changed its thinking on HIV reporting. The agency is calling for a change in state policy that would require New York physicians to report cases of HIV infection to the state’s health department.

Although all states require reporting of AIDS cases, only about half require HIV reporting, and these states account for only about a quarter of all AIDS cases. New York, with the highest proportion of reported AIDS cases (69 per 100,000 population), has not required reporting of those with the virus who have not progressed to AIDS. A decision in that direction by the New York legislature, which is now expected, could impact on policy in other states.

The GMHC has changed its stance in light of the advances in treatment, primarily the use of “cocktails” containing protease inhibitors, that in many HIV-positive individuals may prevent progression to AIDS, at least temporarily. Thus, early knowledge of infection could be life-saving and outweighs concerns that reporting would cause people to shy away from testing.

The policy change was also prompted by the recognition that tracking AIDS cases but not HIV infection does not reflect the true epidemiology of the disease.

The GMHC proposes that confidentiality be protected by a system of coded identification reporting, rather than reporting names, and objects to any efforts to require contact of the sexual partners of people identified as HIV positive (or of those who have shared needles with them).

Coded systems are currently in use in Maryland and Texas, but a recent Centers for Disease Control and Prevention report found that use of codes to track HIV infection in those states may not have resulted in accurate counts.

Recent Videos
3 experts in this video
3 experts in this video
3 experts in this video
3 experts in this video
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
According to Megan Mullins, PhD, MPH, challenging cultural norms surrounding death and dying may reduce the receipt of low-value end-of-life cancer care.
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
Related Content